Literature DB >> 3185747

Dose-response curves of pirenzepine in man in relation to M1- and M2-cholinoceptor occupancy.

H F Pitschner1, A Wellstein.   

Abstract

The aim of the present study was to investigate the M-cholinoceptor subtype selectivity of pirenzepine in man. In parallel with effects on the heart rate and salivary flow, M-cholinoceptor subtype occupancy by antagonist present in plasma samples was detected in radioreceptor assays. Bovine cerebral cortex membranes labelled with 3H-pirenzepine (M1) and rat salivary gland membranes labelled with 3H-N-methylscopolamine (M2) were used in these in vitro assays. A half-maximal occupancy of M1-cholinoceptors in the in vitro assay of plasma samples was detected after 0.25 mg of pirenzepine i.v. The respective half-maximal M2-cholinoceptor occupancy was observed after 10 mg. Doses less than 3 mg decreased the heart rate by maximally 10.7 beats/min with an ED50 of about 0.1 mg. An increase in heart rate (relative to control values) was observed at doses greater than 10 mg. This bivalent dose-response relationship was also observed after beta-blockade. Salivary flow tended to increase at doses less than 1 mg and was half-maximally inhibited after 10 mg. Combining the in vitro and in vivo results, the typical antimuscarinic effects (tachycardia and inhibition of salivary flow) can be attributed to the blockade of M2-cholinoceptors, whereas the reduction of heart rate coincides with the blockade of the M1-subtype. With respect to the typical antimuscarinic effects, pirenzepine was 70-fold less potent than atropine; in contrast, with respect to the reduction of heart rate, pirenzepine was equipotent with atropine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3185747     DOI: 10.1007/BF00174872

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  22 in total

1.  Clinical pharmacology and pharmacokinetics of clonidine.

Authors:  C T Dollery; D S Davies; G H Draffan; H J Dargie; C R Dean; J L Reid; R A Clare; S Murray
Journal:  Clin Pharmacol Ther       Date:  1976-01       Impact factor: 6.875

2.  Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase.

Authors:  D W Gil; B B Wolfe
Journal:  J Pharmacol Exp Ther       Date:  1985-03       Impact factor: 4.030

Review 3.  Muscarinic receptor subtypes: a critique of the current classification and a proposal for a working nomenclature.

Authors:  R M Eglen; R L Whiting
Journal:  J Auton Pharmacol       Date:  1986-12

4.  Dose-response curves of pirenzepine in man in relation to M1- and M2-cholinoceptor occupancy.

Authors:  H F Pitschner; A Wellstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

5.  Selective labelling of M1-receptors in autonomic ganglia with 3H-pirenzepine.

Authors:  E Giraldo; E Monferini; R Hammer
Journal:  Arzneimittelforschung       Date:  1985

6.  Pirenzepine distinguishes between different subclasses of muscarinic receptors.

Authors:  R Hammer; C P Berrie; N J Birdsall; A S Burgen; E C Hulme
Journal:  Nature       Date:  1980-01-03       Impact factor: 49.962

7.  Effects of pirenzepine and atropine on vagal and cholinergic gastric secretion and gastrin release and on heart rate in the dog.

Authors:  B I Hirschowitz; J Fong; E Molina
Journal:  J Pharmacol Exp Ther       Date:  1983-05       Impact factor: 4.030

Review 8.  Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases.

Authors:  A A Carmine; R N Brogden
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

9.  Psychometric studies of pirenzepine.

Authors:  E Kuhn; R Honzák
Journal:  Scand J Gastroenterol Suppl       Date:  1980

10.  Sympathetic Nerve Stimulation on the perfused rat heart. Affinities of N-methylatropine and pirenzepine at pre- and postsynaptic muscarine receptors.

Authors:  H Fuder; D Rink; E Muscholl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-02       Impact factor: 3.000

View more
  8 in total

1.  Different muscarinic receptors mediate autoinhibition of acetylcholine release and vagally-induced vasoconstriction in the rat isolated perfused heart.

Authors:  I T Bognar; B Beinhauer; P Kann; H Fuder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-04       Impact factor: 3.000

2.  Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics.

Authors:  K Taguchi; R F Schäfers; M C Michel
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

Review 3.  Muscarinic receptors and drugs in cardiovascular medicine.

Authors:  P A van Zwieten; H N Doods
Journal:  Cardiovasc Drugs Ther       Date:  1995-02       Impact factor: 3.727

4.  Cardiac muscarinic receptors decrease with age. In vitro and in vivo studies.

Authors:  O E Brodde; U Konschak; K Becker; F Rüter; U Poller; J Jakubetz; J Radke; H R Zerkowski
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

5.  Dose-response curves of pirenzepine in man in relation to M1- and M2-cholinoceptor occupancy.

Authors:  H F Pitschner; A Wellstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

6.  Inhibitory and excitatory muscarinic receptors modulating the release of acetylcholine from the postganglionic parasympathetic neuron of the chicken heart.

Authors:  G Brehm; R Lindmar; K Löffelholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-10       Impact factor: 3.000

7.  Complex dose-response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors.

Authors:  A Wellstein; H F Pitschner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-07       Impact factor: 3.000

8.  Effects of fitness and age on the response to vagotonic atropine.

Authors:  Kichang Lee; Glen Picard; Stacy D Beske; Gyu-Sam Hwang; J Andrew Taylor
Journal:  Auton Neurosci       Date:  2008-03-05       Impact factor: 3.145

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.